DEFEROXAMINE MESYLATE - Generic Drug Details

What are the generic drug sources for deferoxamine mesylate and what is the scope of patent protection?

Deferoxamine mesylate is the generic ingredient in two branded drugs marketed by Dr Reddys, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, West-ward Pharms Int, and Novartis, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for deferoxamine mesylate. Five suppliers are listed for this compound.

Summary for DEFEROXAMINE MESYLATE

US Patents:	0
Tradenames:	2
Applicants:	6
NDAs:	6
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	6
Patent Applications:	2,408
Drug Prices:	Drug price trends for DEFEROXAMINE MESYLATE
What excipients (inactive ingredients) are in DEFEROXAMINE MESYLATE?	DEFEROXAMINE MESYLATE excipients list
DailyMed Link:	DEFEROXAMINE MESYLATE at DailyMed

See drug prices for DEFEROXAMINE MESYLATE

Recent Clinical Trials for DEFEROXAMINE MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research	Phase 2
Aditya S. Pandey, MD	Phase 2
General Hospital of Beijing PLA Military Region	Phase 1/Phase 2

See all DEFEROXAMINE MESYLATE clinical trials

Pharmacology for DEFEROXAMINE MESYLATE

Drug Class	Iron Chelator
Mechanism of Action	Iron Chelating Activity

Medical Subject Heading (MeSH) Categories for DEFEROXAMINE MESYLATE

Siderophores

Anatomical Therapeutic Chemical (ATC) Classes for DEFEROXAMINE MESYLATE

V03AC	Iron chelating agents
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

US Patents and Regulatory Information for DEFEROXAMINE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	DEFEROXAMINE MESYLATE	deferoxamine mesylate	INJECTABLE;INJECTION	078718-001	Sep 15, 2009	AP	RX	No	No
Gland Pharma Ltd	DEFEROXAMINE MESYLATE	deferoxamine mesylate	INJECTABLE;INJECTION	207384-002	Sep 29, 2017	AP	RX	No	No
Dr Reddys	DEFEROXAMINE MESYLATE	deferoxamine mesylate	INJECTABLE;INJECTION	076806-002	Mar 31, 2006		DISCN	No	No
Hospira	DEFEROXAMINE MESYLATE	deferoxamine mesylate	INJECTABLE;INJECTION	076019-002	Mar 17, 2004	AP	RX	No	Yes
West-ward Pharms Int	DEFEROXAMINE MESYLATE	deferoxamine mesylate	INJECTABLE;INJECTION	078086-002	May 30, 2007	AP	RX	No	No
Novartis	DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267-001	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

Expired US Patents for DEFEROXAMINE MESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	DESFERAL	deferoxamine mesylate	INJECTABLE;INJECTION	016267-001	Approved Prior to Jan 1, 1982	3,471,476

DEFEROXAMINE MESYLATE Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Deferoxamine Mesylate

Introduction

Deferoxamine mesylate, a potent iron chelator, is increasingly crucial in the treatment of iron overload conditions such as thalassemia, hemochromatosis, and acute iron intoxication. Here, we delve into the market dynamics and financial trajectory of this vital drug.

Market Size and Projections

The Deferoxamine Mesylate market has shown significant growth and is expected to continue this trend. As of 2023, the market was valued at USD 100 billion and is projected to reach USD 147.75 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 5% from 2024 to 2031[1].

Segmentation of the Market

The market is segmented based on several key factors:

By Type

• Injectable
• Powder
• Capsules
• Tablets

Each form has its own market share and growth prospects, with injectable forms being particularly prominent due to their efficacy in acute treatments[1].

By Application

• Iron overload treatment
• Thalassemia treatment
• Chronic kidney disease management
• Acute iron poisoning
• Research & development

The increasing prevalence of iron overload diseases such as thalassemia and hemochromatosis is driving demand across these applications[1].

By Geography

• North America
• Europe
• Asia-Pacific
• South America
• Middle-East and Africa

Regional growth varies, with Asia-Pacific expected to be a significant growth driver due to improving healthcare infrastructure and increasing awareness of iron overload conditions[1].

Drivers of Market Growth

Several factors are propelling the growth of the Deferoxamine Mesylate market:

Increasing Prevalence of Iron Overload Diseases

The rise in chronic illnesses requiring iron chelation therapy, such as transfusion-dependent anemia and thalassemia major, is a primary driver. Early diagnosis and treatment awareness among patients and healthcare professionals are also contributing to market growth[1][3].

Improvements in Healthcare Infrastructure

Enhancements in healthcare access, particularly in developing nations, are making Deferoxamine Mesylate more accessible. Government initiatives to improve healthcare infrastructure and favorable reimbursement policies are further boosting market expansion[1][3].

Technological Advancements

Advancements in medication delivery systems and formulations have improved treatment outcomes and patient compliance. These innovations are crucial in maintaining the market's growth trajectory[1][3].

Regulatory Support

Supportive government programs and regulatory frameworks are facilitating the market's expansion. Research and development efforts aimed at broadening the therapeutic applications of Deferoxamine Mesylate are expected to open new business opportunities[1][3].

Competitive Landscape

The Deferoxamine Mesylate market is characterized by a competitive landscape involving both established and emerging players. Key companies profiled in the market include:

• Novartis
• Apotex
• Sun Pharmaceutical
• Sanofi
• Mylan
• Cipla
• Dr. Reddy's Laboratories
• Teva Pharmaceuticals
• Fresenius Kabi
• Hikma Pharmaceuticals[1]

These companies are engaged in various market strategies such as new product launches, collaborations, company expansions, and acquisitions to maintain their competitive edge.

Financial Performance and Investment Opportunities

The financial performance of the Deferoxamine Mesylate market is robust, with significant investment opportunities identified across various segments. Here are some key points:

Most Profitable Segments

The injectable form and iron overload treatment segments are among the most profitable for investment. These segments are expected to expand rapidly and hold a significant market share[1].

Regional Expansion Strategies

Understanding market dynamics in different geographical areas is crucial for developing regional expansion strategies. The Asia-Pacific region, in particular, offers substantial growth potential due to its large patient population and improving healthcare infrastructure[1].

Competitive Strategies

Analyzing the market share of leading players, their new service/product launches, collaborations, and other strategic moves can help in understanding the competitive landscape and making informed investment decisions[1].

Challenges and Side Effects

While Deferoxamine Mesylate is a highly effective drug, it is not without its challenges and side effects. Common side effects include hearing loss, vision problems, and decreased urination. These side effects necessitate careful monitoring and management by healthcare professionals[2].

Future Outlook

The future outlook for the Deferoxamine Mesylate market is promising, driven by continued research and development, improving healthcare infrastructure, and increasing awareness of iron overload conditions.

"Strong market expansion for deferoxamine is being driven by an increase in the prevalence of iron overload illnesses such as hemochromatosis and thalassemia. The growing knowledge of the problems linked to iron buildup in the body among patients and medical professionals is also fueling this increase."[3]

Key Takeaways

• The Deferoxamine Mesylate market is valued at USD 100 billion in 2023 and is expected to reach USD 147.75 billion by 2031.
• The market is driven by the increasing prevalence of iron overload diseases, improvements in healthcare infrastructure, and technological advancements.
• Key segments include injectable forms and iron overload treatment.
• Asia-Pacific is a significant growth driver due to its large patient population and improving healthcare infrastructure.
• The competitive landscape involves major players like Novartis, Apotex, and Sun Pharmaceutical.

FAQs

1. What is Deferoxamine Mesylate used for? Deferoxamine Mesylate is used to treat acute iron intoxication and chronic iron overload due to transfusion-dependent anemia, thalassemia, and other conditions[2].

2. What is the projected growth rate of the Deferoxamine Mesylate market? The Deferoxamine Mesylate market is expected to grow at a CAGR of 5% from 2024 to 2031[1].

3. Which regions are expected to drive the growth of the Deferoxamine Mesylate market? The Asia-Pacific region is anticipated to be a significant growth driver due to its large patient population and improving healthcare infrastructure[1].

4. What are the common side effects of Deferoxamine Mesylate? Common side effects include hearing loss, vision problems, decreased urination, and other systemic issues[2].

5. Which companies are key players in the Deferoxamine Mesylate market? Key companies include Novartis, Apotex, Sun Pharmaceutical, Sanofi, Mylan, and others[1].

Sources

1. Market Research Intellect - Global Deferoxamine Mesylate Market Size and Projections
2. Leukemia and Lymphoma Society - Deferoxamine mesylate
3. Market Research Intellect - Deferoxamine Market Size & Growth | Global Industry Analysis [2031]